Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Transgene Biotek has filed the annual compliance certificate required under Clause 40(9) of SEBI's Listing Obligations and Disclosure Requirements (LODR) Regulations for the financial year ended 31 March 2025. The certificate, issued by Practicing Company Secretary Geeta Serwani & Associates after examining the company's share registers and related records, confirms that the company received no requests for share transfer, sub-division, consolidation, renewal, exchange, or endorsement of calls/allotment monies during FY 2024-25. The share registry is maintained by Big Share Services Pvt Ltd. The filing was signed by Chairman & Managing Director Dr K Koteswara Rao and submitted to BSE on 24 April 2025.
This is a routine annual regulatory filing with no material impact on shareholders or the stock price. It simply confirms that no share transfer or related activity took place during the year, reflecting stable shareholding records.